Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study

被引：0
|
作者：
Yamada, T. [1 ]
Katayama, Y. [2 ]
Watanabe, S. [3 ]
Watanabe, K. [4 ]
Takeda, T. [5 ]
Chihara, Y. [6 ]
Shiotsu, S. [7 ]
Hibino, M. [8 ]
Harada, T. [9 ]
Takayama, K. [1 ]
机构：
[1] Kyoto Prefectural Univ Med, Pulm Med, Kyoto, Japan
[2] Kyoto Prefectural Univ Med, Resp, Kyoto, Japan
[3] Niigata Univ Med & Dent Hosp, Dept Resp Med & Infect Dis, Niigata, Japan
[4] Tokyo Metropolitan Canc & Infect Dis Ctr Komagome, Thorac Oncol & Resp Med Dept, Bunkyo Ku, Tokyo, Japan
[5] Japanese Red Cross Kyoto Daini Hosp, Resp Med, Kyoto, Japan
[6] Uji Tokushukai Med Ctr, Resp Med, Uji, Japan
[7] Kyoto First Red Cross Hosp Kyoto Daiichi Sekijyuj, Oncol, Kyoto, Japan
[8] Shonan Fujisawa Tokushukai Hosp, Resp Med, Fujisawa, Kanagawa, Japan
[9] Fukuchiyama City Hosp, Med Oncol, Fukuchiyama, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.608
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
529P
引用
收藏
页码：S1676 / S1676
页数：1
相关论文
共 50 条
  • [31] Docetaxel and non-small cell lung cancer
    Le Guen, Y
    Le Cesne, A
    BULLETIN DU CANCER, 2004, 91 (03) : 263 - 270
  • [32] Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
    Boutsikou, Eftimia
    Kontakiotis, Theodoros
    Zarogoulidis, Paul
    Darwiche, Kaid
    Eleptheriadou, Ellada
    Porpodis, Konstantinos
    Galaktidou, Grammati
    Sakkas, Leonidas
    Hohenforst-Schmidt, Wolfgang
    Tsakiridis, Kosmas
    Karaiskos, Theodoros
    Zarogoulidis, Konstantinos
    ONCOTARGETS AND THERAPY, 2013, 6 : 125 - 134
  • [33] A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer
    Kouroussis, C
    Agelaki, S
    Mavroudis, D
    Kakolyris, S
    Androulakis, N
    Kalbakis, K
    Souglakos, J
    Mallas, K
    Bozionelou, V
    Pallis, A
    Adamtziki, H
    Georgoulias, V
    ANTICANCER RESEARCH, 2003, 23 (1B) : 785 - 791
  • [34] Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non-small cell lung cancer
    Heineman, Thomas
    Baumgart, Megan
    Nanavati, Charvi
    Gabrail, Nash
    Van Wart, Scott A.
    Mager, Donald E.
    Maneval, Daniel C.
    Fathallah, Anas M.
    Sekulovich, Rose E.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (05): : 1875 - 1885
  • [35] Phase II study of combination of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer
    Mitsuoka, Shigeki
    Kudoh, Shinzoh
    Kimura, Tatsuo
    Yoshimura, Naruo
    Hirata, Kazuto
    ANNALS OF ONCOLOGY, 2006, 17 : 227 - 227
  • [36] A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer
    Bennouna, J
    Monnier, A
    Rivière, A
    Milleron, B
    Lemarie, E
    Trillet-Lenoir, V
    Soussan-Lazard, K
    Berille, J
    Douillard, JY
    EUROPEAN JOURNAL OF CANCER, 2000, 36 (09) : 1107 - 1112
  • [37] Docetaxel (Taxotere®) plus cisplatin:: an active and well-tolerated combination in patients with advanced non-small cell lung cancer
    Le Chevalier, T
    Monnier, A
    Douillard, JY
    Ruffie, P
    Sun, XS
    Belli, L
    Ibrahim, N
    Bougon, N
    Bérille, J
    EUROPEAN JOURNAL OF CANCER, 1998, 34 (13) : 2032 - 2036
  • [38] Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer
    Adjei, AA
    Argiris, A
    Murren, JR
    SEMINARS IN ONCOLOGY, 1999, 26 (05) : 32 - 40
  • [39] Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer
    Le Chevalier, T
    Bérille, J
    Zalcberg, JR
    Millward, MJ
    Monnier, A
    Douillard, JY
    McKeage, MJ
    James, R
    Soulas, F
    Loret, C
    Bougon, N
    Bizzari, JP
    SEMINARS IN ONCOLOGY, 1999, 26 (03) : 13 - 18
  • [40] Combination Chemotherapy with Docetaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer
    W. Schuette
    I. Bork
    B. Wollschläger
    S. Schädlich
    Clinical Drug Investigation, 2001, 21 : 161 - 168
12345